CLINICAL TRIAL: PACTG 1020-A: NOVEL PROTEASE INHIBITOR (BMS-232632) IN HIV-INFEC

临床试验：PACTG 1020-A：用于 HIV-INFEC 的新型蛋白酶抑制剂 (BMS-232632)

• 批准号: 7718391
• 负责人: William Borkowsky
• 金额: $ 7.33万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2009-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7718391
• 关键词: Adult; BMS232632; Childhood; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Enrollment; Funding; Grant; Hyperbilirubinemia; Institution; Label; Licensing; Patients; Phase; Protease Inhibitor; Research; Research Personnel; Resistance; Resources; Source; Therapeutic; Toxic effect; United States National Institutes of Health; novel; peptidomimetics

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a multicenter phase I/II open-label study of a novel protease inhibitor (BMS-232632) in HIV-1-infected pediatric patients. A wide variety of patients with varying types of therapeutic resistance (excepting noncompliance) are eligible for enrollment. BMS-232632 is a C2-symmetrical azapeptide structurally different from licensed protease inhibitors, which are peptidomimetic. The major toxicity to date in adults has been hyperbilirubinemia. Enrollment into this study continues. Results are not yet available.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这是对HIV-1感染的儿科患者的新型蛋白酶抑制剂（BMS-232632）的多中心I/II期开放标签研究。 各种各样的患者具有不同类型的治疗性耐药性（非依从性除外）有资格参加。 BMS-232632是一种与肽瘤的许可蛋白酶抑制剂结构上不同的C2-对称偶氮肽。 迄今为止，成人的主要毒性是高胆红素血症。 这项研究的入学率仍在继续。 结果尚不可用。